Recently, we have shown that RIOK2 is required for maintaining protein synthesis and ribosomal stability in leukemic cells, and we have therefore proposed RIOK2 as a potential therapeutic target for AML therapy [11]. The gene discussed is RIOK2; the disease is acute myeloid leukemia.